Stockscreener 앱 받기
0.4803
1.32%
0.0093
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
Theriva?? Biologics Announces Presentation of Data from Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025 - marketscreener.com
Theriva Biologics (TOVX) to Present Key Retinoblastoma Trial Dat - GuruFocus
Theriva™ Biologics Announces Presentation of Data from - GlobeNewswire
Breakthrough Cancer Drug VCN-01 Takes on Rare Pediatric Eye Cancer and Pancreatic Cancer at ASCO 2025 - Stock Titan
Synthetic Biologics stock plunges to 52-week low of $0.47 By Investing.com - Investing.com South Africa
Synthetic Biologics stock plunges to 52-week low of $0.47 - Investing.com Australia
Theriva Biologics: Q1 Earnings Snapshot - Midland Daily News
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics (TOVX) Achieves Milestone in Pancreatic Cancer Trial | TOVX Stock News - GuruFocus
Theriva Biologics Posts Narrower Loss In Q1 - Nasdaq
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results | TOVX Stock News - GuruFocus
Breakthrough: New Cancer Drug Shows Survival Benefits in Advanced Pancreatic Cancer Trial Results - Stock Titan
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Globe and Mail
Theriva Biologics’ (TOVX) Hold Rating Reiterated at Maxim Group - Defense World
Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong - MSN
Theriva Biologics Completes $7.5 Million Public Offering - TipRanks
Theriva Biologics Announces Closing of $7.5 Million Public Offering | TOVX Stock News - GuruFocus
Theriva Biologics Closes $7.5 Million Public Offering to Advance Cancer Therapeutics - Nasdaq
Theriva Biologics Announces Closing of $7.5 Million Public Offering - GlobeNewswire
Theriva Biologics Inc (AMEX: TOVX) Shares Are Set To Rise By 2025 - Stocksregister
Theriva Biologics (TOVX) Faces Downgrade After Phase 2b Study Re - GuruFocus
Theriva Biologics (TOVX) Faces Downgrade After Phase 2b Study Results | TOVX Stock News - GuruFocus
TOVX: Theriva Biologics Downgraded by Maxim Group | TOVX Stock N - GuruFocus
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trial - BioWorld MedTech
Theriva™ Biologics Announces Primary Endpoints for Efficacy - GlobeNewswire
Theriva Biologics sets terms for $7.5 million public offering By Investing.com - Investing.com South Africa
Transcript : Theriva Biologics, Inc.Special Call - marketscreener.com
Theriva?? Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in Virage Phase 2B Clinical Trial of Vcn-01 with Gemcitabine/Nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - marketscreener.com
Theriva Biologics Announces Pricing of $7.5 Million Public Offering - citybiz
Theriva Biologics (TOVX) Announces $7.5 Million Public Offering - GuruFocus
Theriva Biologics (TOVX) Announces $7.5 Million Public Offering | TOVX Stock News - GuruFocus
Theriva Biologics Announces Pricing of $7.5 Million Public Offering | TOVX Stock News - GuruFocus
Theriva Biologics Announces Pricing of Public Offering for $7.5 Million to Support Cancer Therapeutics Development - Nasdaq
Theriva Biologics sets terms for $7.5 million public offering - Investing.com
Theriva Biologics (TOVX) Reports Promising Phase 2b Trial Results for VCN-01 | TOVX Stock News - GuruFocus
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - The Manila Times
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 6.8% – Should You Buy? - Defense World
Theriva Biologics Announces Presentation of Data from the - GlobeNewswire
Major Clinical Trial Update: Theriva's SYN-004 Shows Promise in Transplant PatientsKey Data Revealed - Stock Titan
Synthetic Biologics stock plunges to 52-week low at $1.02 - Investing.com Australia
Synthetic Biologics stock plunges to 52-week low at $1.02 By Investing.com - Investing.com South Africa
Theriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025 - Nasdaq
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Ad - GlobeNewswire
Cancer Drug Breakthrough: Independent Committee Confirms Positive Safety Data in Phase 2b Pancreatic Trial - Stock Titan
Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Should You Sell? - Defense World
1.30%
3.35%
자본화:
|
볼륨(24시간):